9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Estimated reading time: < 1 min

Condition: Medical Oncology

Estimated Enrollment: 36

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Maximum tolerated dose (MTD),  Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability,  Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin, Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD

Interventions: BAY 94-9343, Pemetrexed

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: May 23, 2018

Completion Date: September 26, 2019

Last  Posted Date: July 17, 2019

Location: Chicago, Illinois, United States

Website Link: https://ClinicalTrials.gov/show/NCT02639091

Was this article helpful?
Dislike 0